USD 0.0
(0.0%)
Year | Inventory | Inventory Growth |
---|---|---|
2021 | 14.21 Million USD | 142.68% |
2020 | 5.85 Million USD | 0.0% |
Year | Inventory | Inventory Growth |
---|---|---|
2022 Q2 | 16.8 Million USD | 12.56% |
2022 Q1 | 14.93 Million USD | 0.0% |
2021 FY | 14.21 Million USD | 142.68% |
2021 Q2 | 9.76 Million USD | 0.0% |
2020 FY | 5.85 Million USD | 0.0% |
Name | Inventory | Inventory Difference |
---|---|---|
AstraZeneca PLC | 5.41 Billion USD | 99.738% |
Bristol-Myers Squibb Company PFD CONV 2 | 2.66 Billion USD | 99.466% |
CSPC Pharmaceutical Group Limited | 442.43 Million USD | 96.787% |
Novartis AG | 5.91 Billion USD | 99.76% |
PT Kalbe Farma Tbk. | 451.27 Million USD | 96.85% |